These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis. Ridker PM; MacFadyen JG; Thuren T; Libby P Eur Heart J; 2020 Jun; 41(23):2153-2163. PubMed ID: 31504417 [TBL] [Abstract][Full Text] [Related]
11. Effects of Interleukin-1β Inhibition on Incident Hip and Knee Replacement : Exploratory Analyses From a Randomized, Double-Blind, Placebo-Controlled Trial. Schieker M; Conaghan PG; Mindeholm L; Praestgaard J; Solomon DH; Scotti C; Gram H; Thuren T; Roubenoff R; Ridker PM Ann Intern Med; 2020 Oct; 173(7):509-515. PubMed ID: 32744862 [TBL] [Abstract][Full Text] [Related]
12. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Ridker PM; Thuren T; Zalewski A; Libby P Am Heart J; 2011 Oct; 162(4):597-605. PubMed ID: 21982649 [TBL] [Abstract][Full Text] [Related]
13. Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure. Everett BM; Cornel JH; Lainscak M; Anker SD; Abbate A; Thuren T; Libby P; Glynn RJ; Ridker PM Circulation; 2019 Mar; 139(10):1289-1299. PubMed ID: 30586730 [TBL] [Abstract][Full Text] [Related]
14. Relationship of Interleukin-1β Blockade With Incident Gout and Serum Uric Acid Levels: Exploratory Analysis of a Randomized Controlled Trial. Solomon DH; Glynn RJ; MacFadyen JG; Libby P; Thuren T; Everett BM; Ridker PM Ann Intern Med; 2018 Oct; 169(8):535-542. PubMed ID: 30242335 [TBL] [Abstract][Full Text] [Related]
15. TET2-Driven Clonal Hematopoiesis and Response to Canakinumab: An Exploratory Analysis of the CANTOS Randomized Clinical Trial. Svensson EC; Madar A; Campbell CD; He Y; Sultan M; Healey ML; Xu H; D'Aco K; Fernandez A; Wache-Mainier C; Libby P; Ridker PM; Beste MT; Basson CT JAMA Cardiol; 2022 May; 7(5):521-528. PubMed ID: 35385050 [TBL] [Abstract][Full Text] [Related]
16. Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials? Ridker PM Trans Am Clin Climatol Assoc; 2013; 124():174-90. PubMed ID: 23874021 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of IL1β by Canakinumab May Be Effective against Diverse Molecular Subtypes of Lung Cancer: An Exploratory Analysis of the CANTOS Trial. Wong CC; Baum J; Silvestro A; Beste MT; Bharani-Dharan B; Xu S; Wang YA; Wang X; Prescott MF; Krajkovich L; Dugan M; Ridker PM; Martin AM; Svensson EC Cancer Res; 2020 Dec; 80(24):5597-5605. PubMed ID: 33023946 [TBL] [Abstract][Full Text] [Related]
18. The cost-effectiveness of canakinumab for secondary prevention of cardiovascular disease: The Australian healthcare perspective. Zomer E; Liew D; Tonkin A; Trauer JM; Ademi Z Int J Cardiol; 2019 Jun; 285():1-5. PubMed ID: 30686493 [TBL] [Abstract][Full Text] [Related]
19. Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis. Ridker PM Circ Res; 2019 Feb; 124(3):437-450. PubMed ID: 30702995 [TBL] [Abstract][Full Text] [Related]
20. Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Ridker PM; Howard CP; Walter V; Everett B; Libby P; Hensen J; Thuren T; Circulation; 2012 Dec; 126(23):2739-48. PubMed ID: 23129601 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]